Frontiers in Psychiatry
July 29, 2026
Caitlyn Hanna Sams, Jasmine Davis, Anuradha Ramdas et al.
We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic symptoms. Two patients underwent the De La Haye Psilocybin Treatment Protocol (DPTP), which integrates micro- and high-doses (combined psilocybin...
Journal of AOAC International
August 13, 2025
Kimberley Foster, Isaac Morrison, S. Daniel et al.
4 citations
Abstract Background The consumption of dried fruiting bodies of Psilocybe cubensis can be traced over centuries, guided by Mesoamerican curanderas, Western medical practitioners, and fungal enthusiasts, all seeking mental wellbeing. There is a notable resurgence in interest both in the fungal biomass and psilocybin, the psychoactive tryptamine, despite the global regulatory restrictions,...
Fungal biology
February 1, 2024
Kimberley Foster, Isaac Morrison, Marshall Tyler et al.
3 citations
Psychedelic fungi have experienced a surge in interest in recent years. Most notably, the fungal secondary metabolite psilocybin has shown tremendous promise in the treatment of various psychiatric disorders. The mushroom species that produce this molecule are poorly understood. Here we sought to examine for the first time, the response of a psilocybin-producing species Psilocybe cubensis to...
Computational biology and chemistry
June 1, 2023
William Irvine, Marshall Tyler, Rupika Delgoda
11 citations
Nearly all mushrooms of the Psilocybe genus contain the natural product psilocybin, which is a psychoactive alkaloid derived from l-tryptophan. Considering their use in ancient times, as well as their psychedelic properties, these mushrooms have re-emerged with psychotherapeutic potential for treating depression, which has triggered increased pharmaceutical interest. However, the psilocybin...